Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of MVA-NP+M1 Adjunct to QIV in Adults
NCT03880474Phase 2Terminated
- Sponsor
- Barinthus Biotherapeutics
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of VTP-100 in influenza, sponsored by Barinthus Biotherapeutics. Started Mar 2019; status: terminated.
02
Drugs
VTP-100
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03880474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880474.